UBS AM
KNSA icon

UBS AM’s Kiniksa Pharmaceuticals KNSA Stock Holding History

UBS AM’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178K Sell
2,790
-41,735
-94% -$2.16M ﹤0.01% 2742
2026
Q1 		$2.14M Buy
44,525
+2,123
+5% +$94K ﹤0.01% 2012
2025
Q4 		$1.75M Sell
42,402
-13,117
-24% -$526K ﹤0.01% 1939
2025
Q3 		$2.16M Sell
55,519
-49,186
-47% -$1.6M ﹤0.01% 1714
2025
Q2 		$2.9M Buy
104,705
+48,729
+87% +$1.24M ﹤0.01% 1973
2025
Q1 		$1.24M Sell
55,976
-715
-1% -$14.7K ﹤0.01% 2216
2024
Q4 		$1.12M Buy
56,691
+12,462
+28% +$284K ﹤0.01% 2314
2024
Q3 		$1.11M Buy
+44,229
New +$1.08M ﹤0.01% 2350
2024
Q2 		– Sell
-10,608
Closed -$209K – 2851
2024
Q1 		$209K Hold
10,608
– – ﹤0.01% 2457
2023
Q4 		$186K Hold
10,608
– – ﹤0.01% 2499
2023
Q3 		$184K Hold
10,608
– – ﹤0.01% 2524
2023
Q2 		$114K Hold
10,608
– – ﹤0.01% 2634
2023
Q1 		$114K Sell
10,608
-19,400
-65% -$256K ﹤0.01% 2634
2022
Q4 		$450K Hold
30,008
– – ﹤0.01% 2212
2022
Q3 		$385K Sell
30,008
-5,482
-15% -$62.5K ﹤0.01% 2436
2022
Q2 		$344K Hold
35,490
– – ﹤0.01% 2431
2022
Q1 		$353K Hold
35,490
– – ﹤0.01% 2552
2021
Q4 		$418K Hold
35,490
– – ﹤0.01% 2615
2021
Q3 		$404K Buy
+35,490
New +$462K ﹤0.01% 2559

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

UBS AM's KNSA Position: Q2 2026 in Review

UBS AM reduced its Kiniksa Pharmaceuticals (KNSA) stake by 94% in Q2 2026, selling an estimated $2.16M and leaving 2,790 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #2742.

UBS AM first reported a position in KNSA in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.9M in Q2 2025. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • UBS AM held 2,790 shares of Kiniksa Pharmaceuticals worth $178K as of Q2 2026.
  • UBS AM sold 41,735 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.16M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2742 holding.
  • UBS AM first reported a position in Kiniksa Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • UBS AM's Kiniksa Pharmaceuticals position peaked at $2.9M in Q2 2025.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.